1. Scrip
  2. >>Leadership

Bausch + Lomb Taps A Familiar Face, Brent Saunders, As Next CEO

 
• By Jessica Merrill

Saunders will oversee the eye specialist, returning to the firm where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.

Brent Saunders
Brent Saunders • Source: Bausch + Lomb

Industry veteran Brent Saunders is returning to the pharmaceutical sector and a company he knows particularly well: Bausch + Lomb Inc., the eye specialist where he first cut his teeth as a CEO in 2010. B+L announced the appointment of Saunders to the CEO role on 15 February. He will succeed Joseph Papa, who led the business through some tumultuous years beginning in 2016 when it was still under Bausch Health Companies Inc. and formerly known as Valeant

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.